© The Canadian Journal of Urology™; 19(Supplement 1); October 2012
22.
Chapple C, Steers W, Norton P et al. A pooled analysis of three
phase III studies to investigate the efficacy, tolerability and safety
of darifenacin, a muscarinic M3 selective receptor antagonist, in
the treatment of overactive bladder.
BJU Int
2005;95(7):993-1001.
23.
Cardozo L, Lisec M, Millard R et al. Randomized, double-blind
placebo controlled trial of the once daily antimuscarinic agent
solifenacin succinate in patients with overactive bladder.
J Urol
2004;172(5
Pt 1):1919-1924.
24.
Haab F, Cardozo L, Chapple C, Ridder AM, Solifenacin Study
Group. Long-term open-label solifenacin treatment associated
with persistence with therapy in patients with overactive
bladder syndrome.
Eur Urol
2005;47(3):376-384.
25.
Diokno AC, Appell RA, Sand PK, OPERA Study Group et al.
Prospective, randomized, double-blind study of the efficacy and
tolerability of the extended-release formulations of oxybutynin
and tolterodine for overactive bladder: Results of the OPERA
trial.
Mayo Clin Proc
2003;78(6):687-695.
26.
Dmochowski RR, Sand PK, Zinner NR, Transdermal
Oxybutynin Study Group et al. Comparative efficacy and safety
of transdermal oxybutynin and oral tolterodine versus placebo
in previously treated patients with urge and mixed urinary
incontinence.
Urology
2003;62(2):237-242.
27.
Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive
function of the elderly population: effects of darifenacin.
J Urol
2005;173(2):493-498.
28.
Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of
tolterodine, trospium chloride, and oxybutynin on the central
nervous system.
J Clin Pharmacol
2001;41(6):636-644.
29.
Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D’Angelo K.
Identification of medications that cause cognitive impairment
in older people: the case of oxybutynin chloride.
J AmGeriatr Soc
1998;46(1):8-13.
30.
Kay G, Crook T, Rekeda L et al. Differential effects of the
antimuscarinic agents darifenacin and oxybutynin ER on
memory in older subjects.
Eur Urol
2006;50(2):317-326.
31.
Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and
tolerability of extended-release once-daily tolterodine treatment
foroveractivebladderinolderversusyoungerpatients.
JAmGeriatr
Soc
2002;50(5):799-807.
32.
Paguria D, O’Conner RC, GuralnickML. Antimuscarinic drugs:
review of the cognitive impact when used to treat overactive
bladder in elderly patients.
Curr Urol Rep
2011;12(5):351-357.
33.
Herschorn S, Swift S, Guan Z et al. Comparison of fesoterodine
and tolterodine extended release for the treatment of overactive
bladder: a head-to-head placebo-controlled trial.
BJU Int
2010;105(1):58-66.
34.
Kay GG, Staskin DR, Macdiarmid S, McIlwain M, Dahl NV.
Cognitive effects of oxybutyninchloride topical gel inolder healthy
subjects: a 1-week, randomized, double-blind, placebo- andactive-
controlled study.
Clin Drug Investig
2012;32(10):707-714.
35.
Barkin J, Folia. Emerging therapies.
Can J Urol
2012;19(
Suppl 1):
49-53.
36.
Wagg A, Verdejo C, Molander U. Review of cognitive
impairment with antimuscarinic agents in elderly patients with
overactive bladder.
Int J Clin Pract
2010;64(9):1279-1286.
37.
Kaplan SA, RoehrbornCG, Rovner ES, CarlssonM, BavendamT,
Guan Z. Tolterodine and tamsulosin for treatment of
men with lower urinary tract symptoms and overactive
bladder: a randomized controlled trial.
JAMA
2006;296(19):
2319-2328.
38.
Hendrix SL, Cochrane BB, Nygaard IE et al. Effects of estrogen
with andwithout progestin on urinary incontinence.
JAMA
2005;
293(8):935-948.
39.
Andersson KE. Treatment of overactive bladder: other drug
mechanisms.
Urology
2000;55(5
A Suppl 1):51-57.
40.
Glazener CM, Evans JH, Peto RE. Tricyclic and related drugs for
nocturnal enuresis in children.
Cochrane Database Syst Rev
2003;3:
CD002117.
41.
ResnickNM. Urinary incontinence.
Lancet
1995;346(8967):94-99.
42.
Resnick NM, Yalla SV. Geriatric Incontinence and Voiding
dysfunction. In: Wein AJ, Kavoussi LR, Novick AC, Partin
AW, Peters CA, ed. Campbell-Walsh Urology 9
th
edition,
Philadelphia: Saunders Elsevier, 2007:2305-2321.
43.
Norgaard JP, Rittig S, Djurhuus JC. Nocturnal enuresis:
an approach to treatment based on pathogenesis.
J Pediatr
1989;114(4
Pt 2):705-710.
44.
RobsonWL, Norgaard JP, LeungAK. Hyponatremia in patients
with nocturnal enuresis treatedwith DDAVP.
Eur J Pediatr
1996;
155(11):959-962.
45.
Schwab M, Ruder H. Hyponatraemia and cerebral convulsion
due toDDAVPadministration in patientswith enuresis nocturna
or urine concentration testing.
Eur J Pediatr
1997;156(8):668.
46.
Herschorn S, Gajewski J, Ethans K et al. Efficacy of botulinum
toxin A injection for neurogenic detrusor overactivity and
urinary incontinence: a randomized, double-blind trial.
J Urol
2011;185(6):2229-2235.
47.
Dmochowski R, Chapple C, Nitti VWet al. Efficacy and safety of
onabotulinumtoxinAfor idiopathic overactive bladder: a double-
blind, placebo controlled, randomized, dose ranging trial.
J Urol
2010;184(6):2416-2422.
48.
Peters KM, Macdiarmid SA, Wooldridge LS et al. Randomized
trial of percutaneous tibial nerve stimulation versus extended-
release tolterodine: results from the overactive bladder
innovative therapy trial.
J Urol
2009;182(3):1055-1061.
49.
Vandoninck V, Van Balken MR, Finazzi Agró E et al. Posterior
tibial nerve stimulation in the treatment of urge incontinence.
Neurourol Urodyn
2003;22(1):17-23.
50.
Schmidt RA, Jonas U, Oleson KAet al. Sacral nerve stimulation
for treatment of refractory urinary urge incontinence. Sacral
Nerve Stimulation Study Group.
J Urol
1999;162(2):352-357.
51.
van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP et al.
Results of sacral neuromodulation therapy for urinary voiding
dysfunction: outcomes of a prospective, worldwide clinical
study.
J Urol
2007;178(5):2029-2034.
9
Medical management of overactive bladder
